Recombinant Human Hepatocyte nuclear factor 3-alpha (FOXA1)

In Stock
Code CSB-EP008794HU
Size $306
Order now
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Greater than 85% as determined by SDS-PAGE.
Target Names
Uniprot No.
Research Area
Epigenetics and Nuclear Signaling
Alternative Names
Forkhead box protein A1 (Transcription factor 3A) (TCF-3A)
Homo sapiens (Human)
Expression Region
Target Protein Sequence
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
56.6 kDa
Protein Length
Full Length
Tag Info
N-terminal 10xHis-tagged and C-terminal Myc-tagged
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

The recombinant Human FOXA1 protein expression involves transfecting e.coli cells with a DNA expression vector containing the gene encoding the recombinant protein of interest (1-472aa) and then culturing the cells so that they express the desired protein. The protein features a N-terminal 10xHis tag and C-terminal Myc tag fusion. The recombinant Human FOXA1 protein is collected and purified from the cell lysate through affinity purification. Its purity is greater than 85%, as measured by SDS-PAGE.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites. Binds DNA with the consensus sequence 5'-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3'. Proposed to play a role in translating the epigenetic signatures into cell type-specific enhancer-driven transcriptional programs. Its differential recruitment to chromatin is dependent on distribution of histone H3 methylated at 'Lys-5' (H3K4me2) in estrogen-regulated genes. Involved in the development of multiple endoderm-derived organ systems such as liver, pancreas, lung and prostate; FOXA1 and FOXA2 seem to have at least in part redundant roles. Modulates the transcriptional activity of nuclear hormone receptors. Is involved in ESR1-mediated transcription; required for ESR1 binding to the NKX2-1 promoter in breast cancer cells; binds to the RPRM promoter and is required for the estrogen-induced repression of RPRM. Involved in regulation of apoptosis by inhibiting the expression of BCL2. Involved in cell cycle regulation by activating expression of CDKN1B, alone or in conjunction with BRCA1. Originally described as a transcription activator for a number of liver genes such as AFP, albumin, tyrosine aminotransferase, PEPCK, etc. Interacts with the cis-acting regulatory regions of these genes. Involved in glucose homeostasis.
Gene References into Functions
  1. High FOXA1 expression is associated with the pathogenesis of gastric cancer. PMID: 30066917
  2. FoxA1 might be related to the development and differentiation of secretory coil-like structures, as well as the secretory function of the 3D reconstructed eccrine sweat glands. PMID: 29909922
  3. TUG1 promoted osteosarcoma cell proliferation and suppressed apoptosis by regulating the miR-212-3p/FOXA1 axis. PMID: 29793327
  4. miR-760 should be considered as a tumor suppressor since it negatively regulates the oncogene protein FOXA1 and regulated TRAIL sensitivity in Non-small cell lung cancer cells. PMID: 29665655
  5. As a tumor suppressor, FOXA1 targets PIK3R1 directly to inhibit PI3K/Akt signaling pathway, thus exerting a negative regulatory effect on proliferation, migration, and invasion of HCC in male patients. PMID: 29208003
  6. miR212 suppresses renal cell carcinoma (RCC) proliferation and invasion by modulating FOXA1, suggesting that miR212 may have potential as a therapeutic target in RCC. PMID: 29115609
  7. the results of the present study suggested that FOXA1 is a potential oncogene in NSCLC PMID: 29115441
  8. During the ensuing weeks, the PAX2/FOXA1 boundary progressively extended cranially such that by 21 weeks the entire vaginal epithelium was FOXA1-reactive and PAX2-negative. This observation supports Bulmer's proposal that human vaginal epithelium derives solely from urogenital sinus epithelium PMID: 28918284
  9. The transcription factor FOXA1 directly bound to the PLOD2 promoter, and turned on PLOD2 transcription. In summary, our findings revealed a regulatory mechanism of NSCLC metastasis through EGFR-PI3K/AKT-FOXA1-PLOD2 pathway. PMID: 29072684
  10. maintenance of the cancer cell state is dependent on recruitment of Mediator and Cohesin through FOXA and master transcription factors PMID: 27739523
  11. overexpression of GATA3 and FOXA1 cooperate with PPAR activation to drive transdifferentiation of a basal bladder cancer cells to a luminial phenotype. PMID: 27924948
  12. Results found FOXA1 to be hypermethylated in breast tumors from African American (AA) versus European American (EA) women with ER- cancer, and methylation levels showed strong inverse relationships with both mRNA and protein levels. A significant positive association was identified between parity and FOXA1 methylation in tumors from AA women who did not breastfeed. PMID: 28756535
  13. High expression of FOXA1 is associated with breast tumor. PMID: 28534958
  14. High FOXA1 expression was significantly associated with presence of lymph node metastasis (LNM), low tumour-infiltrating lymphocytes (TILs), and submucosal invasion. PMID: 28843920
  15. Results provide evidence that the atypical expression of FOXA1 transcriptional factor is an important player in psoriasis, as it inhibits maturation of naive T cells into a Treg subpopulation, therefore contributing to the development of psoriatic skin lesions. PMID: 28849568
  16. Authors demonstrated that ER(alpha), GATA3 and FOXA1 form a transcriptional complex with Ell3 to regulate IL-20 expression in ER(+) breast cancer cells. FOXA1 represses IL-20 expression, whereas GATA3 and ER(alpha) activate it. PMID: 28514748
  17. the findings show that squamous and micropapillary bladder cancers have different expression patterns of CK14 and FOXA1 and suggest that they arise from distinct precursors. PMID: 28721490
  18. rs4442975 may not confer a risk of breast cancer occurrence or progression in the Chinese Han population. PMID: 27835577
  19. As a transcriptionally regulated program, urothelial differentiation operates as a heterarchy, wherein GATA3 is able to co-operate with FOXA1 to drive expression of luminal marker genes, but that P63 has potential to transrepress expression of the same genes. PMID: 28282036
  20. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. PMID: 27791031
  21. Findings suggested FOXA1 may act as an anti-oncogene in gastric cancer (GC) cells. Low-level expression of FOXA1 protein was confirmed in GC tissues and cell lines. FOXA1 over-expression could significantly affect cell proliferation, apoptosis and tumor invasion of GC cells, which may be resulted by reversing EMT. PMID: 29129808
  22. High expression of FOXA1 is an independent prognostic parameter in ERG negative prostate cancer PMID: 29029032
  23. A molecular mechanism by which Estradiol antagonizes GR-dependent induction of specific genes by preventing the recruitment of the pioneer factors FOXA1 and FOXA2 in a physiologically relevant model. PMID: 28938408
  24. Results show that c-Abl phosphorylates FoxA1 at multiple sites. Tyr429 and Tyr464 were identified as the major phosphorylation sites in the FoxA1 C-terminal region. This c-Abl-mediated phosphorylation of FoxA1 promotes the activation of estrogen signaling by inducing its binding to histones. PMID: 27883218
  25. MLL3 binding was dependent on FOXA1, indicating that FOXA1 recruits MLL3 to chromatin. MLL3 silencing decreased H3K4me1 at enhancer elements but had no appreciable impact on H3K4me3 at enhancer elements. We propose a mechanism whereby the pioneer factor FOXA1 recruits the chromatin modifier MLL3 to facilitate the deposition of H3K4me1 histone marks, subsequently demarcating active enhancer elements PMID: 27926873
  26. FoxA1 discriminates between medullary thyroid carcinoma and tumors of follicular derivation with sensitivity and specificity greater than calcitonin and carcinoembryonic antigen. PMID: 28546130
  27. FOXA1 loss may play a significant role in enabling prostate cancer progression to neuroendocrine prostate cancer, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention. PMID: 28319070
  28. Low FOXA1 expression is associated with breast cancer invasion and metastasis. PMID: 27524420
  29. the distinct mechanisms by which GATA2 and FOXA1 regulate AR cistrome and suggest that FOXA1 acts upstream of GATA2 and AR in determining hormone-dependent gene expression in prostate cancer. PMID: 26751772
  30. Study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in pancreatic ductal adenocarcinoma metastasis. PMID: 28757253
  31. Studies indicate that microRNA miR-212 exerts its inhibitory effect on hepatocellular carcinoma (HCC) by inhibiting forkhead transcription factor FOXA1 expression. PMID: 27999212
  32. FOXA1 is expressed by basal cells of squamous epithelium, pre-invasion lesions of the uterine cervix and the head/neck and almost half invasive cervical and head/neck carcinomas, supporting its possible implication in HPV associated carcinomas. PMID: 28209524
  33. CREB1/FoxA1 signaling is a targetable driver of prostate cancer progression and serves as a biomarker of poor clinical outcomes. PMID: 26743006
  34. miR-93 may promote the process of epithelial-mesenchymal transition in endometrial carcinoma cells by targeting FOXA1. PMID: 27829043
  35. conclusion, our results demonstrated that miR24 inhibits breast cancer cells invasion by targeting OGT and reducing FOXA1 stability. These results also indicated that OGT might be a potential target for the diagnosis and therapy of breast cancer metastasis. PMID: 28455227
  36. FOXA1 is not only able to recognize but also remodel the epigenetic signatures at lineage-specific enhancers, which is mediated, at least in part, by a feed-forward regulatory loop between FOXA1 and TET1. PMID: 27257062
  37. Based on these results, we suggest that FOXA1 plays a catalytic role in ovarian cancer pathogenesis and development by affecting the expression of the above-mentioned proteins. PMID: 28488543
  38. these results suggest that FOXA1 suppresses expression of IL6 through inhibition of NF-kappaB recruitment to the IL6 promoter in an ERalpha-independent manner and that reduction in FOXA1 expression induces IL6 expression and contributes to cancer stem cell-like properties in TAM-R cells. PMID: 28270510
  39. These results suggest a positional-nucleosome-oriented accessing model for Pioneer factors seeking target motifs, in which FOXA1 can examine each underlying DNA nucleotide. PMID: 27458208
  40. Down-regulation of TRPS1 by miR-373, acting as a transcriptional activator, promotes epithelial-mesenchymal transition (EMT) and metastasis by repressing FOXA1 transcription, expanding upon its previously reported role as a transcription repressor. PMID: 26969828
  41. FOXA1 is found in ovarian mucinous and Brenner tumours PMID: 28238418
  42. the results of the present study indicated that FOXA1 may be considered a potential prognostic marker, and may promote tumor growth of CRC by upregulating YAP expression. PMID: 27484093
  43. meta-analysis showed that high expression of FOXA1 in breast cancer patients was a good prognostic indicator for survival outcome. PMID: 27212698
  44. FOXA1 promotes cell senescence in EC by interaction with p16INK4a. PMID: 27349269
  45. There is significantly increased esophageal squamous cell carcinoma risk associated with the FOXA1 rs7144658 T > C polymorphism among male patients. PMID: 27050876
  46. Meta-analysis results clearly point to an important role of FOXA1 and FOXA2 gene regulatory networks in the etiology of Alzheimer's disease PMID: 26890743
  47. show that ER and GR both have the ability to alter the genomic distribution of the FoxA1 pioneer factor. Single-molecule tracking experiments reveal a highly dynamic interaction of FoxA1 with chromatin in vivo; FoxA1 factor is not associated with footprints at its binding sites throughout the genome; findings support a model wherein interactions between transcription factors and pioneer factors are highly dynamic. PMID: 27062924
  48. findings suggest a key role for GalNAc-T4 in the estrogen pathway through FOXA1 glycosylation PMID: 26541755
  49. The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH PMID: 26658322
  50. Loss of Interdependent Binding by the FoxO1 and FoxA1/A2 Forkhead Transcription Factors Culminates in Perturbation of Active Chromatin Marks and Binding of Transcriptional Regulators at Insulin-sensitive Genes. PMID: 26929406

Show More

Hide All

Subcellular Location
Tissue Specificity
Highly expressed in prostate and ESR1-positive breast tumors. Overexpressed in esophageal and lung adenocarcinomas.
Database Links

HGNC: 5021

OMIM: 602294

KEGG: hsa:3169

STRING: 9606.ENSP00000250448

UniGene: Hs.163484

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To